Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group.

Abstract:

:The selectivity of histone deacetylase inhibitors (HDACis) is greatly impacted by the zinc binding groups. In an effort to search for novel zinc binding groups, we applied a parallel medicinal chemistry (PMC) strategy to quickly synthesize substituted benzamide libraries. We discovered a series containing 2-substituted benzamides as the zinc binding group which afforded highly selective and potent HDAC3 inhibitors, exemplified by compound 16 with a 2-methylthiobenzamide. Compound 16 inhibited HDAC3 with an IC50 of 30 nM and with unprecedented selectivity of >300-fold over all other HDAC isoforms. Interestingly, a subtle change of the 2-methylthio to a 2-hydroxy benzamide in 20 retains HDAC3 potency but loses all selectivity over HDAC 1 and 2. This significant difference in selectivity was rationalized by X-ray crystal structures of HDACis 16 and 20 bound to HDAC2, revealing different binding modes to the catalytic zinc ion. This series of HDAC3 selective inhibitors served as tool compounds for investigating the minimal set of HDAC isoforms that must be inhibited for the HIV latency activation in a Jurkat 2C4 cell model and potentially as leads for selective HDAC3 inhibitors for other indications.

journal_name

ACS Med Chem Lett

authors

Liu J,Yu Y,Kelly J,Sha D,Alhassan AB,Yu W,Maletic MM,Duffy JL,Klein DJ,Holloway MK,Carroll S,Howell BJ,Barnard RJO,Wolkenberg S,Kozlowski JA

doi

10.1021/acsmedchemlett.0c00462

subject

Has Abstract

pub_date

2020-10-13 00:00:00

pages

2476-2483

issue

12

issn

1948-5875

journal_volume

11

pub_type

杂志文章
  • Identification of New Nonsteroidal RORα Ligands; Related Structure-Activity Relationships and Docking Studies.

    abstract::A high throughput screen was developed to identify novel, nonsteroidal RORα agonists. Among the validated hit compounds, the 4-(4-(benzyloxy)phenyl)-5-carbonyl-2-oxo-1,2,3,4-tetrahydropyrimidine scaffold was the most prominent. Among the numerous analogues tested, compounds 8 and 9 showed the highest activity. Key str...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml300471d

    authors: Dubernet M,Duguet N,Colliandre L,Berini C,Helleboid S,Bourotte M,Daillet M,Maingot L,Daix S,Delhomel JF,Morin-Allory L,Routier S,Walczak R

    更新日期:2013-04-10 00:00:00

  • Discovery of Membrane-Bound Pyrophosphatase Inhibitors Derived from an Isoxazole Fragment.

    abstract::Membrane-bound pyrophosphatases (mPPases) regulate energy homeostasis in pathogenic protozoan parasites and lack human homologues, which makes them promising targets in e.g. malaria. Yet only few nonphosphorus inhibitors have been reported so far. Here, we explore an isoxazole fragment hit, leading to the discovery of...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.9b00537

    authors: Johansson NG,Turku A,Vidilaseris K,Dreano L,Khattab A,Ayuso Pérez D,Wilkinson A,Zhang Y,Tamminen M,Grazhdankin E,Kiriazis A,Fishwick CWG,Meri S,Yli-Kauhaluoma J,Goldman A,Boije Af Gennäs G,Xhaard H

    更新日期:2020-02-17 00:00:00

  • Structure-Guided Optimization of Replication Protein A (RPA)-DNA Interaction Inhibitors.

    abstract::Replication protein A (RPA) is the major human single stranded DNA (ssDNA)-binding protein, playing essential roles in DNA replication, repair, recombination, and DNA-damage response (DDR). Inhibition of RPA-DNA interactions represents a therapeutic strategy for cancer drug discovery and has great potential to provide...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.9b00440

    authors: Gavande NS,VanderVere-Carozza PS,Pawelczak KS,Vernon TL,Jordan MR,Turchi JJ

    更新日期:2020-01-02 00:00:00

  • Discovery of tetrahydroisoquinoline-based CXCR4 antagonists.

    abstract::A de novo hit-to-lead effort involving the redesign of benzimidazole-containing antagonists of the CXCR4 receptor resulted in the discovery of a novel series of 1,2,3,4-tetrahydroisoquinoline (TIQ) analogues. In general, this series of compounds show good potencies (3-650 nM) in assays involving CXCR4 function, includ...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml400183q

    authors: Truax VM,Zhao H,Katzman BM,Prosser AR,Alcaraz AA,Saindane MT,Howard RB,Culver D,Arrendale RF,Gruddanti PR,Evers TJ,Natchus MG,Snyder JP,Liotta DC,Wilson LJ

    更新日期:2013-09-05 00:00:00

  • Design of Dual Inhibitors of Soluble Epoxide Hydrolase and LTA4 Hydrolase.

    abstract::Multitarget anti-inflammatory drugs interfering with the arachidonic acid cascade exhibit superior efficacy. In this study, a prototype dual inhibitor of soluble epoxide hydrolase (sEH) and LTA4 hydrolase (LTA4H) with submicromolar activity toward both targets has been designed and synthesized. Preliminary structure-a...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.9b00330

    authors: Hiesinger K,Schott A,Kramer JS,Blöcher R,Witt F,Wittmann SK,Steinhilber D,Pogoryelov D,Gerstmeier J,Werz O,Proschak E

    更新日期:2019-10-30 00:00:00

  • Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.

    abstract::Inhibition of the lipid kinase PI3Kδ is a promising principle to treat B and T cell driven inflammatory diseases. Using a scaffold deconstruction-reconstruction strategy, we identified 4-aryl quinazolines that were optimized into potent PI3Kδ isoform selective analogues with good pharmacokinetic properties. With compo...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.6b00119

    authors: Hoegenauer K,Soldermann N,Stauffer F,Furet P,Graveleau N,Smith AB,Hebach C,Hollingworth GJ,Lewis I,Gutmann S,Rummel G,Knapp M,Wolf RM,Blanz J,Feifel R,Burkhart C,Zécri F

    更新日期:2016-06-02 00:00:00

  • Maturing from embryonic to adult policy on stem cell therapeutics.

    abstract::The National Institutes of Health (NIH) closure of the agency's Center for Regenerative Medicine (CRM), which focused on therapeutic development of induced pluripotent stem cells (iPS), was caused by the lack of progress in practical development of the iPSs for use in human therapies. As the NIH evaluates priorities i...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml500396z

    authors: Maguire G

    更新日期:2014-10-08 00:00:00

  • Himbacine-derived thrombin receptor antagonists: c7-spirocyclic analogues of vorapaxar.

    abstract::We have synthesized several C7-spirocyclic analogues of vorapaxar and evaluated their in vitro activities against PAR-1 receptor. Some of these analogues showed activities and rat plasma levels comparable to vorapaxar. Compound 5c from this series showed excellent PAR-1 activity (K i = 5.1 nM). We also present a model...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml500008w

    authors: Chelliah MV,Eagen K,Guo Z,Chackalamannil S,Xia Y,Tsai H,Greenlee WJ,Ahn HS,Kurowski S,Boykow G,Hsieh Y,Chintala M

    更新日期:2014-03-11 00:00:00

  • JAK2 JH2 Fluorescence Polarization Assay and Crystal Structures for Complexes with Three Small Molecules.

    abstract::A competitive fluorescence polarization (FP) assay is reported for determining binding affinities of probe molecules with the pseudokinase JAK2 JH2 allosteric site. The syntheses of the fluorescent 5 and 6 used in the assay are reported as well as Kd results for 10 compounds, including JNJ7706621, NVP-BSK805, and filg...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.7b00154

    authors: Newton AS,Deiana L,Puleo DE,Cisneros JA,Cutrona KJ,Schlessinger J,Jorgensen WL

    更新日期:2017-05-17 00:00:00

  • Discovery of Potent and Selective Leads against Toxoplasma gondii Dihydrofolate Reductase via Structure-Based Design.

    abstract::Current treatment of toxoplasmosis targets the parasite's folate metabolism through inhibition of dihydrofolate reductase (DHFR). The most widely used DHFR antagonist, pyrimethamine, was introduced over 60 years ago and is associated with toxicity that can be largely attributed to a similar affinity for parasite and h...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.6b00328

    authors: Welsch ME,Zhou J,Gao Y,Yan Y,Porter G,Agnihotri G,Li Y,Lu H,Chen Z,Thomas SB

    更新日期:2016-09-17 00:00:00

  • Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist.

    abstract::Incorporation of polar functionality into a series of highly potent calcitonin gene-related peptide (CGRP) receptor antagonists was explored in an effort to improve pharmacokinetics. This strategy identified piperazinone analogues that possessed improved solubility at acidic pH and increased oral bioavailability in mo...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml900016y

    authors: Bell IM,Gallicchio SN,Wood MR,Quigley AG,Stump CA,Zartman CB,Fay JF,Li CC,Lynch JJ,Moore EL,Mosser SD,Prueksaritanont T,Regan CP,Roller S,Salvatore CA,Kane SA,Vacca JP,Selnick HG

    更新日期:2010-01-12 00:00:00

  • Discovery of a novel broad-spectrum antifungal agent derived from albaconazole.

    abstract::Synthesis of a strict structural analogue of albaconazole in which the quinazolinone ring is fused by a thiazole moiety led to the discovery of a new triazole with broad-spectrum antifungal activity. Compound I exhibited high in vitro activity against pathogenic Candida species and filamentous fungi and showed prelimi...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml300429p

    authors: Guillon R,Pagniez F,Picot C,Hédou D,Tonnerre A,Chosson E,Duflos M,Besson T,Logé C,Le Pape P

    更新日期:2013-01-17 00:00:00

  • Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4).

    abstract::GSK2798745, a clinical candidate, was identified as an inhibitor of the transient receptor potential vanilloid 4 (TRPV4) ion channel for the treatment of pulmonary edema associated with congestive heart failure. We discuss the lead optimization of this novel spirocarbamate series and specifically focus on our strategi...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.9b00274

    authors: Brooks CA,Barton LS,Behm DJ,Eidam HS,Fox RM,Hammond M,Hoang TH,Holt DA,Hilfiker MA,Lawhorn BG,Patterson JR,Stoy P,Roethke TJ,Ye G,Zhao S,Thorneloe KS,Goodman KB,Cheung M

    更新日期:2019-07-15 00:00:00

  • Effectively delivering a unique hsp90 inhibitor using star polymers.

    abstract::We report the synthesis of a novel heat shock protein 90 (hsp90) inhibitor conjugated to a star polymer. Using reversible addition-fragmentation chain-transfer (RAFT) polymerization, we prepared star polymers comprised of PEG attached to a predesigned functional core. The stars were cross-linked using disulfide linker...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml400082b

    authors: Kim SJ,Ramsey DM,Boyer C,Davis TP,McAlpine SR

    更新日期:2013-07-25 00:00:00

  • Synthesis and antimalarial activity of 3,3-spiroanellated 5,6-disubstituted 1,2,4-trioxanes.

    abstract::Novel 3,3-spiroanellated 5-aryl, 6-arylvinyl-substituted 1,2,4-trioxanes 19-34 have been synthesized and appraised for their antimalarial activity against multidrug-resistant Plasmodium yoelii nigeriensis in Swiss mice by oral route at doses ranging from 96 mg/kg × 4 days to 24 mg/kg × 4 days. The most active compound...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml300188t

    authors: Maurya R,Soni A,Anand D,Ravi M,Raju KS,Taneja I,Naikade NK,Puri SK,Wahajuddin,Kanojiya S,Yadav PP

    更新日期:2012-12-11 00:00:00

  • Design and Catalyzed Activation of Tak-242 Prodrugs for Localized Inhibition of TLR4-Induced Inflammation.

    abstract::Tak-242 (resatorvid), a Toll-like Receptor 4 (TLR4) inhibitor, has been identified as a potent suppressor of innate inflammation. As a strategy to target Tak-242 to select tissue, four TLR4-inactive prodrugs were synthesized for activation via two different release mechanisms. Two nitrobenzyl Tak-242 prodrugs released...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.9b00518

    authors: Plunk MA,Alaniz A,Olademehin OP,Ellington TL,Shuford KL,Kane RR

    更新日期:2020-01-03 00:00:00

  • Synthesis and Cardiac Imaging of (18)F-Ligands Selective for β1-Adrenoreceptors.

    abstract::A series of potent and selective β1-adrenoreceptor ligands were identified (IC50 range, 0.04-0.25 nM; β1/β2 selectivity range, 65-450-fold), labeled with the PET radioisotope fluorine-18 and evaluated in normal Sprague-Dawley rats. Tissue distribution studies demonstrated uptake of each radiotracers from the blood poo...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml1002458

    authors: Radeke HS,Purohit A,Harris TD,Hanson K,Jones R,Hu C,Yalamanchili P,Hayes M,Yu M,Guaraldi M,Kagan M,Azure M,Cdebaca M,Robinson S,Casebier D

    更新日期:2011-07-22 00:00:00

  • Highly Efficient Synthesis of 1,3-Dihydroxy-2-carboxycarbazole and Its Neuroprotective Effects.

    abstract::Carbazoles represent a family of tricyclic compounds that widely appeared in nature. Numerous studies have revealed a diverse array of bioactivity associated with this scaffold. In the present study, a novel and highly efficient methodology for preparing 1,3-dihydroxy-2-carboxycarbazole from indole-3-acetic acid and M...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.5b00158

    authors: Liu K,Zhang S

    更新日期:2015-07-10 00:00:00

  • Small Macrocycles As Highly Active Integrin α2β1 Antagonists.

    abstract::Starting from clinical candidates Firategrast, Valategrast, and AJM-300, a series of novel macrocyclic platelet collagen receptor α2β1 antagonists were developed. The amino acid derived low molecular weight 14-18-membered macrocycles turned out to be highly active toward integrin α2β1 with IC50s in the low nanomolar r...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml4004556

    authors: Halland N,Blum H,Buning C,Kohlmann M,Lindenschmidt A

    更新日期:2014-01-10 00:00:00

  • Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode.

    abstract::General control nonderepressible 2 (GCN2) is a master regulator kinase of amino acid homeostasis and important for cancer survival in the tumor microenvironment under amino acid depletion. We initiated studies aiming at the discovery of novel GCN2 inhibitors as first-in-class antitumor agents and conducted modificatio...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.9b00400

    authors: Fujimoto J,Kurasawa O,Takagi T,Liu X,Banno H,Kojima T,Asano Y,Nakamura A,Nambu T,Hata A,Ishii T,Sameshima T,Debori Y,Miyamoto M,Klein MG,Tjhen R,Sang BC,Levin I,Lane SW,Snell GP,Li K,Kefala G,Hoffman ID,Ding

    更新日期:2019-09-19 00:00:00

  • Discovery of 1,4-Naphthoquinones as a New Class of Antiproliferative Agents Targeting GPR55.

    abstract::A new series of 1,4-naphthoquinones, bearing various cyclic and aliphatic amines on C2, was designed and synthesized to identify antiproliferative agents for triple-negative breast cancer, which represents a clinical challenge without targeted therapies. Among naphthoquinones, 2a and 3a inhibited the proliferation of ...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.8b00333

    authors: Badolato M,Carullo G,Caroleo MC,Cione E,Aiello F,Manetti F

    更新日期:2019-02-15 00:00:00

  • Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.

    abstract::Somatic point mutations at a key arginine residue (R132) within the active site of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in cancer cells, resulting in the production of d-2-hydroxyglutarate (2-HG), an oncometabolite. Elevated 2-HG levels are implicated in epigenetic alt...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.7b00421

    authors: Popovici-Muller J,Lemieux RM,Artin E,Saunders JO,Salituro FG,Travins J,Cianchetta G,Cai Z,Zhou D,Cui D,Chen P,Straley K,Tobin E,Wang F,David MD,Penard-Lacronique V,Quivoron C,Saada V,de Botton S,Gross S,Dang L,Y

    更新日期:2018-01-19 00:00:00

  • 3,5-Disubstituted-indole-7-carboxamides as IKKβ Inhibitors: Optimization of Oral Activity via the C3 Substituent.

    abstract::IκB kinase β (IKKβ or IKK2) is a key regulator of nuclear factor kappa B (NF-κB) and has received attention as a therapeutic target. Herein we report on the optimization of a series of 3,5-disubstituted-indole-7-carboxamides for oral activity. In doing so, we focused attention on potency, ligand efficiency (LE), and p...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.8b00291

    authors: Kerns JK,Busch-Petersen J,Fu W,Boehm JC,Nie H,Muratore M,Bullion A,Lin G,Li H,Davis R,Lin X,Lakdawala AS,Cousins R,Field R,Payne J,Miller DD,Bamborough P,Christopher JA,Baldwin I,Osborn RR,Yonchuk J,Webb E,Rum

    更新日期:2018-10-30 00:00:00

  • Synthesis and Evaluation of Noviose Replacements on Novobiocin that Manifest Anti-proliferative Activity.

    abstract::Structural modifications to the coumarin core and benzamide side chain of novobiocin have successfully transformed the natural product from a selective DNA gyrase inhibitor into a potent inhibitor of the Hsp90 C-terminus. However, no SAR studies have been conducted on the noviose appendage, which represents the rate-l...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml100070r

    authors: Zhao H,Kusuma BR,Blagg BS

    更新日期:2010-07-13 00:00:00

  • Radiosynthesis of (11)C-Levetiracetam: A Potential Marker for PET Imaging of SV2A Expression.

    abstract::The multistep preparation of (11)C-levetiracetam ((11)C-LEV) was carried out by a one-pot radiosynthesis with 8.3 ± 1.6% (n = 8) radiochemical yield in 50 ± 5.0 min. Briefly, the propionaldehyde was converted to propan-1-imine in situ as labeling precursor by incubation with ammonia. Without further separation, the im...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml500285t

    authors: Cai H,Mangner TJ,Muzik O,Wang MW,Chugani DC,Chugani HT

    更新日期:2014-08-19 00:00:00

  • Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors.

    abstract::Potent JNK3 isoform selective inhibitors were developed from a thiophenyl-pyrazolourea scaffold. Through structure activity relationship (SAR) studies utilizing enzymatic and cell-based assays, and in vitro and in vivo drug metabolism and pharmacokinetic (DMPK) studies, potent and highly selective JNK3 inhibitors with...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.0c00533

    authors: Feng Y,Park H,Bauer L,Ryu JC,Yoon SO

    更新日期:2020-12-13 00:00:00

  • Steroidomimetic Tetrahydroisoquinolines for the Design of New Microtubule Disruptors.

    abstract::Structure-activity relationship translation offers an expeditious means for discovery of new active series. This approach was applied to discover tetrahydroisoquinoline (THIQ)-based steroidomimetic microtubule disruptors. The two A-ring elements of a three-point steroidal pharmacophore were incorporated into a THIQ-ba...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml200232c

    authors: Leese MP,Jourdan F,Dohle W,Kimberley MR,Thomas MP,Bai R,Hamel E,Ferrandis E,Potter BV

    更新日期:2012-01-12 00:00:00

  • Cystine-based MBioF for Maintaining the Antioxidant-Oxidant Balance in Airway Diseases.

    abstract::Reactive oxygen species, contributing to oxidant-antioxidant imbalance, initiate damage to the airways cells, inflammatory processes, and further pathophysiological effects. Enhancing antioxidant properties is the main prophylactic and therapeutic challenge. In this work, a newly synthesized and biocompatible structur...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.8b00468

    authors: Wiśniewski M,Bieniek A,Roszek K,Czarnecka J,Bolibok P,Ferrer P,da Silva I,Terzyk AP

    更新日期:2018-11-19 00:00:00

  • Discovery of G Protein-Biased EP2 Receptor Agonists.

    abstract::To identify G protein-biased and highly subtype-selective EP2 receptor agonists, a series of bicyclic prostaglandin analogues were designed and synthesized. Structural hybridization of EP2/4 dual agonist 5 and prostacyclin analogue 6, followed by simplification of the ω chain enabled us to discover novel EP2 agonists ...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.5b00455

    authors: Ogawa S,Watanabe T,Sugimoto I,Moriyuki K,Goto Y,Yamane S,Watanabe A,Tsuboi K,Kinoshita A,Kigoshi H,Tani K,Maruyama T

    更新日期:2016-01-04 00:00:00

  • Discovery and in Vitro Optimization of 3-Sulfamoylbenzamides as ROMK Inhibitors.

    abstract::Inhibitors of the renal outer medullary potassium channel (ROMK) show promise as novel mechanism diuretics, with potentially lower risk of diuretic-induced hypokalemia relative to current thiazide and loop diuretics. Here, we report the identification of a novel series of 3-sulfamoylbenzamide ROMK inhibitors. Starting...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.7b00481

    authors: Sammons MF,Kharade SV,Filipski KJ,Boehm M,Smith AC,Shavnya A,Fernando DP,Dowling MS,Carpino PA,Castle NA,Zellmer SG,Antonio BM,Gosset JR,Carlo A,Denton JS

    更新日期:2018-01-19 00:00:00